All lobbying filings

SAREPTA THERAPEUTICS, INC.

SAREPTA THERAPEUTICS, INC. filed a Q3 report for SAREPTA THERAPEUTICS, INC. on October 19, 2026.

Lobbying for SAREPTA THERAPEUTICS, INC.

All filings by SAREPTA THERAPEUTICS, INC. · Everything SAREPTA THERAPEUTICS, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Expenses

$160,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Budget/Appropriations

H.R. 9260 - LHHS Appropriations

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment

Science/Technology

National Security Commission on emerging biotechnology policy proposals

Trade (domestic/foreign)

Issues related to Section 232

Bills named in this filing 1

H.R. 9260
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.